


## Lazertinib

<b>Cat. No.:</b>	HY-109061		
<b>CAS No.:</b>	1903008-80-9		
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>34</sub> N <sub>8</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	554.64		
<b>Target:</b>	EGFR		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 9 mg/mL (16.23 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.8030 mL	9.0149 mL	18.0297 mL
	<b>5 mM</b>		0.3606 mL	1.8030 mL	3.6059 mL	
	<b>10 mM</b>		0.1803 mL	0.9015 mL	1.8030 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 0.9 mg/mL (1.62 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.9 mg/mL (1.62 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 0.9 mg/mL (1.62 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	EGFR <sup>T790M</sup>
<b>In Vitro</b>	Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib

---

targets both T790M mutation and activating EGFR mutations (EGFRm) while sparing wild type<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

---

- Patent. US20220177473A1.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA